Age and biologic survival in patients with moderate-to-severe psoriasis: A cohort study from the British Association of Dermatologists Biologics and Immunomodulators Register (BADBIR)

AcnePsoriasis

Drug survival of IL-23 and IL-17 inhibitors versus other biologics for psoriasis: A British Association of Dermatologists Biologics and Immunomodulators Register cohort study

J Eur Acad Dermatol Venereol

Motedayen Aval L, Yiu ZZN, Alabas OA, Griffiths CEM, Reynolds NJ, Hampton PJ, Smith CH, Warren RB, BADBIR Study Group

doi: 10.1111/jdv.20739

Systemic Sclerosis

Total lung capacity is predictive of disease severity and survival in systemic sclerosis: A longitudinal analysis in 2347 patients from the French National Cohort Study

J Autoimmun

Chaigne B, Bense A, Aubourg F, Agard C, Allanore Y, Berezne A, Pugnet G, Hachulla E, Cottin V, Hot A, Dunogue B, Kanagaratnam A, Palat S, Lescoat A, Berthier S, Chatelus E, Rivière S, Launay D, Truchetet ME, Dinh-Xuan AT, Mouthon L, French Systemic Sclerosis Network

doi: 10.1016/j.jaut.2025.103391

Rheumatoid Arthritis

A cohort study on the associations between age at natural menopause and rheumatoid arthritis in postmenopausal women from the Canadian Longitudinal Study on Aging

Semin Arthritis Rheum

Kesibi D, Rotondi M, Edgell H, Tamim H

doi: 10.1016/j.semarthrit.2025.152747

Further Publications Immunology

Association of Cutaneous Immune-related Adverse Events with Overall Survival and Progression-free Survival in Oncology Patients Receiving Immune Checkpoint Inhibitors: A Prospective Study of 189 Patients in a Spanish Tertiary Care Hospital

Acta Derm Venereol

Juan-Carpena G, Martínez Banaclocha N, Palazón Cabanes JC, Niveiro-de Jaime M, Betlloch Mas I, Blanes-Martínez M

doi: 10.2340/actadv.v105.42023

Further Publications Dermatology

Prognostic factors for patients with cancer-associated dermatomyositis: a retrospective, multicenter cohort study of 73 patients

Rheumatology (Oxford)

Teboul A, Allenbach Y, Tubach F, Belin L, Cassius C, Demortier J, Dossier A, Faucon C, Kasser C, Mekinian A, Monseau G, Fouchard M, Chambrelan E, Viguier M, Kluger N, Mahévas T, Bergeret B, Bachmeyer C, Lenormand C, Hotz C, Diaz E, Cordel N, Benveniste O, Bessis D, Bouaziz JD, Chasset F

doi: 10.1093/rheumatology/keae629

Psoriasis

Repeated Switching Between CT-P17 and EU Reference Adalimumab in Patients with Moderate-to-Severe Chronic Plaque Psoriasis: A Randomized, Double-Blind, Active-Controlled, Phase 3, Interchangeability Study

Adv Ther

Lebwohl MG, Koo JY, Jaworski J, Trefler J, Daniluk S, Dudek A, Baran W, Owczarek W, Kolinek J, Brzewski P, Sikora M, Krogulec M, Kim S, Bae Y, Jeon D, Choi E, Cha J, Lee H, Choi S, Pariser DM

doi: 10.1007/s12325-024-03100-8

Psoriasis

A Randomized Phase III Study to Compare Efficacy and Safety of BAT2206 (Proposed Ustekinumab Biosimilar) with Reference Ustekinumab in Patients with Moderate to Severe Plaque Psoriasis

J Am Acad Dermatol

Man X, Zaharieva K, Pulka G, Zebrowska A, Deng Y, Mekokishvili L, Yang X, Qi Y, Gu C, Dong Q, Zheng M

doi: 10.1016/j.jaad.2024.10.104

Psoriasis

Highly selective, allosteric inhibition of TYK2 with oral ESK-001 in patients with moderate-to-severe plaque psoriasis: Results from STRIDE, a 12-week, randomized, double-blinded, placebo-controlled, dose-ranging Phase 2 study

J Am Acad Dermatol

Blauvelt A, Arenberger P, Sauder MB, Couvillion M, Rubio RG, Vlahakis NE, Ucpinar S, Ma G, Hitraya E, Tilley MK, Papp KA, STRIDE investigators

doi: 10.1016/j.jaad.2025.07.013

Psoriasis

A Phase 3, Randomized, Double-blind, Active-controlled Clinical Study to Compare BAT2206, a Ustekinumab Biosimilar, with Ustekinumab Reference Product in Patients with Moderate-to-severe Psoriasis: Treatment Period 2 Results (Post Week 28 to Week 52)

J Am Acad Dermatol

Man X, Zaharieva K, Pulka G, Żebrowska A, Deng Y, Mekokishvili L, Yang X, Qi Y, Gu C, Dong Q, Zheng M

doi: 10.1016/j.jaad.2025.08.005

Related content

Drug survival of IL-23 and IL-17 inhibitors versus other biologics for psoriasis: A British Association of Dermatologists Biologics and Immunomodulators Register cohort study

Total lung capacity is predictive of disease severity and survival in systemic sclerosis: A longitudinal analysis in 2347 patients from the French National Cohort Study

A cohort study on the associations between age at natural menopause and rheumatoid arthritis in postmenopausal women from the Canadian Longitudinal Study on Aging

Association of Cutaneous Immune-related Adverse Events with Overall Survival and Progression-free Survival in Oncology Patients Receiving Immune Checkpoint Inhibitors: A Prospective Study of 189 Patients in a Spanish Tertiary Care Hospital

Prognostic factors for patients with cancer-associated dermatomyositis: a retrospective, multicenter cohort study of 73 patients

Repeated Switching Between CT-P17 and EU Reference Adalimumab in Patients with Moderate-to-Severe Chronic Plaque Psoriasis: A Randomized, Double-Blind, Active-Controlled, Phase 3, Interchangeability Study

A Randomized Phase III Study to Compare Efficacy and Safety of BAT2206 (Proposed Ustekinumab Biosimilar) with Reference Ustekinumab in Patients with Moderate to Severe Plaque Psoriasis

Highly selective, allosteric inhibition of TYK2 with oral ESK-001 in patients with moderate-to-severe plaque psoriasis: Results from STRIDE, a 12-week, randomized, double-blinded, placebo-controlled, dose-ranging Phase 2 study

A Phase 3, Randomized, Double-blind, Active-controlled Clinical Study to Compare BAT2206, a Ustekinumab Biosimilar, with Ustekinumab Reference Product in Patients with Moderate-to-severe Psoriasis: Treatment Period 2 Results (Post Week 28 to Week 52)